We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+21.26%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.97B
AUM Growth
+$710M
Cap. Flow
+$33.6M
Cap. Flow %
0.68%
Top 10 Hldgs %
43.85%
Holding
701
New
35
Increased
130
Reduced
246
Closed
41

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$31M
2
BTI icon
British American Tobacco
BTI
+$29.2M
3
SAP icon
SAP
SAP
+$27.1M
4
HOOD icon
Robinhood
HOOD
+$17.9M
5
CLS icon
Celestica
CLS
+$13.7M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$29.1M
2
TSM icon
TSMC
TSM
+$26.3M
3
META icon
Meta Platforms (Facebook)
META
+$23.5M
4
BEKE icon
KE Holdings
BEKE
+$22.1M
5
TCOM icon
Trip.com Group
TCOM
+$17M

Sector Composition

Rank Sector Weight
1 Technology 46.19%
2 Consumer Discretionary 14.25%
3 Communication Services 13.85%
4 Healthcare 7.17%
5 Consumer Staples 6.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
601
Monte Rosa Therapeutics
GLUE
$1.86B
$7.09K ﹤0.01%
1,572
– –
ALT icon
602
Altimmune
ALT
$581M
$7.05K ﹤0.01%
1,821
– –
VNDA icon
603
Vanda Pharmaceuticals
VNDA
$310M
$7.05K ﹤0.01%
1,493
– –
CBL
604
CBL Properties
CBL
$1.86B
$6.93K ﹤0.01%
273
+42
+18% +$1.03K
HUMA icon
605
Humacyte
HUMA
$170M
$6.89K ﹤0.01%
3,295
– –
SLN
606
Silence Therapeutics
SLN
$546M
$6.76K ﹤0.01%
1,165
– –
RNAC icon
607
Cartesian Therapeutics
RNAC
$225M
$6.75K ﹤0.01%
650
– –
TKNO icon
608
Alpha Teknova
TKNO
$273M
$6.7K ﹤0.01%
1,365
– –
FHTX icon
609
Foghorn Therapeutics
FHTX
$301M
$6.69K ﹤0.01%
1,424
– –
ANNX icon
610
Annexon
ANNX
$814M
$6.55K ﹤0.01%
2,729
– –
TRDA icon
611
Entrada Therapeutics
TRDA
$226M
$6.44K ﹤0.01%
958
– –
CRVS icon
612
Corvus Pharmaceuticals
CRVS
$1.12B
$6.38K ﹤0.01%
1,594
– –
INZY
613
DELISTED
Inozyme Pharma
INZY
$6.18K ﹤0.01%
1,544
– –
THRD
614
DELISTED
Third Harmonic Bio
THRD
$6.07K ﹤0.01%
1,118
– –
ALLO icon
615
Allogene Therapeutics
ALLO
$573M
$6.07K ﹤0.01%
5,368
– –
OLMA icon
616
Olema Pharmaceuticals
OLMA
$1.01B
$6.06K ﹤0.01%
1,422
– –
ETR icon
617
Entergy
ETR
$52.4B
$5.99K ﹤0.01%
72
-8,939
-99% -$738K
MXCT icon
618
MaxCyte
MXCT
$112M
$5.89K ﹤0.01%
2,701
– –
RCKT icon
619
Rocket Pharmaceuticals
RCKT
$343M
$5.72K ﹤0.01%
2,333
– –
NGNE icon
620
Neurogene
NGNE
$663M
$5.5K ﹤0.01%
368
– –
OABI icon
621
OmniAb
OABI
$286M
$5.39K ﹤0.01%
3,099
– –
TVGN icon
622
Tevogen Bio Holdings
TVGN
$23.6M
$5.26K ﹤0.01%
84
– –
INBX icon
623
Inhibrx
INBX
$1.17B
$5.12K ﹤0.01%
359
– –
YMAB
624
DELISTED
Y-mAbs Therapeutics
YMAB
$5.01K ﹤0.01%
1,111
– –
ACIU icon
625
AC Immune
ACIU
$236M
$4.98K ﹤0.01%
2,454
– –
23 24
25
26 27

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.03B AUM 40.55% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return

GF Fund Management's Q2 2025 Portfolio in Review

As of Q2 2025, GF Fund Management held 701 positions worth $4.97B, up 17% from $4.26B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

GF Fund Management's Q2 2025 filing shows 35 new, 130 increased, 246 reduced and 41 closed positions. Its largest new stake was Shopify: 120,000 shares worth $13.8M. The largest sale was NVIDIA, an estimated $29.1M.

By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 42% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • GF Fund Management's largest Q2 2025 buy was Shopify: 120,000 shares worth $13.8M.
  • GF Fund Management added most to UnitedHealth in Q2 2025, an estimated $31M increase.
  • GF Fund Management's biggest Q2 2025 reduction was NVIDIA, cutting an estimated $29.1M.
  • GF Fund Management fully exited Salesforce in Q2 2025, selling an estimated $9.77M.
  • GF Fund Management's ten largest holdings make up 44% of its $4.97B portfolio in Q2 2025.
  • GF Fund Management opened 35 new positions and closed 41 in Q2 2025.
  • GF Fund Management's portfolio value rose 17% quarter-over-quarter to $4.97B.

Based on GF Fund Management's 13F filing for Q2 2025, filed 22 Jul 2025.